Clinical trials: Granulocyte Colony-Stimulating Factor
Granulocyte Colony-Stimulating Factor (G-CSF) Mobilization
CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors
Healthy donors are commonly mobilized with granulocyte colony-stimulating factor (G-CSF) to collect peripheral blood stem cells for allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- CHRONO-MOBILIZ (NCT07423728)
- Testing
- G-CSF (Granulocyte colony-stimulating factor)
- Where
- 3 sites in China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Diminished Ovarian Reserve, IVF
Study of G-CSF for DOR in Patients Undergoing IVF
Diminished ovarian reserve (DOR) is defined by reduced follicle counts in women, associated with decreased fertility and lower success rates with In Vitro Fertilization (IVF).
- Conditions
- Diminished Ovarian Reserve, IVF, G-CSF, Granulocyte Colony Stimulating Factor
- Trial name
- NCT07871825
- Testing
- Neupogen 300 μg subcutaneous injection, Subcutaneous injections of a saline solution
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Center for Human Reproduction
Non Small Cell Lung Cancer, Immunotherapy
Effect of G-CSF on MDSC and Cancer Stem-cells Interactions in Non-small Cell Lung Cancers (CIRCUIT)
Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to immunologic (myeloid immunosuppressive cells) and non-immunologic (cancer stem- cells (CSC)) mechanisms.
- Conditions
- Non Small Cell Lung Cancer, Immunotherapy, Granulocyte Colony Stimulating Factor
- Trial name
- CIRCUIT (NCT06711770)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Bordeaux
Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor
Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients
The goal of this clinical trial is to Primary Objectives: 1. To compare the incidence of febrile neutropenia in patients with non-Hodgkin's lymphoma who received early or late granulocyte colony-stimulating factor (G-CSF) during…
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor, Febrile Neutropenia (FN), Myelosuppression Adult
- Trial name
- G-CSF in NHL (NCT06665737)
- Testing
- Early receiving G-CSF group, Late receiving G-CSF group
- Where
- 3 sites in Thailand
- Volunteers
- 126 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Granulocyte Colony-stimulating Factor, Biliary Atresia
Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia
The aim of the study is to evaluate the use of Granulocyte Colony Stimulating Factor (GCSF) on the clinical and biochemical outcome of type 3 biliary atresia post kasai.
- Trial name
- NCT06708572
- Testing
- Granulocyte Colony-Stimulating Factor
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Liver Institute, Egypt
Recurrent Implantation Failure, Granulocyte Colony-Stimulating Factor
Intrauterine Infusion of GCSF and Reproductive Outcomes in Infertile Women with History of RIF
Intrauterine infusion of granulocyte colony stimulating factor and reproductive outcomes in infertile women with history of recurrent implantation failure
- Conditions
- Recurrent Implantation Failure, Granulocyte Colony-Stimulating Factor, Infertility
- Trial name
- NCT04998279
- Testing
- Granulocyte Colony-Stimulating Factor
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Granulocyte Colony-Stimulating Factor
The Value of Peripheral Blood CD34+ Cell Dynamics Monitoring in Autologous Hematopoietic Stem Cell Transplant Mobilization
The aim of this study was to evaluate the difference in the accuracy of CD34+ cell detection by immunomagnetic bead method and flow cytometry in patients with hematologic malignancies pre-treated with stem cell transplantation…
- Trial name
- NCT05970185
- Testing
- PEG-rhG-CSF, G-CSF
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhongnan Hospital
Granulocyte Colony-stimulating Factor, Stem Cell Mobilization
A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSF
Have a comparison between pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) and recombinant human granulocyte-colony stimulating factor (rhG-CSF) for difference in efficacy of hematopoietic…
- Trial name
- NCT05409547
- Testing
- PEG-rhG-CSF
- Volunteers
- 80 people
- Sponsor
- Ning Huang
Granulocyte Colony-Stimulating Factor, PD-1 Inhibitor
G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
Recurrence and metastasis are the main causes of treatment failure of NPC. Immunotherapy is an emerging cancer treatment method, which has less adverse reactions and longer duration compared with chemotherapy.
- Trial name
- NCT05222009
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Granulocyte Colony-Stimulating Factor, Chemotherapy-induced Neutropenia
Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients
Chemotherapy places patients at an increased risk of infection. A medication called granulocyte colony-stimulating factor is given as a daily injection in order to help decrease the risk of infection.
- Conditions
- Granulocyte Colony-Stimulating Factor, Chemotherapy-induced Neutropenia, Chemotherapy-Induced Febrile Neutropenia, Pediatric Cancer
- Trial name
- NCT03823950
- Testing
- Granulocyte Colony-Stimulating Factor
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Mississippi Medical Center
Chemotherapy-induced Neutropenia, Febrile Neutropenia, Drug-Induced
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
This study aims to analyze the effects of long-acting versus short-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer patients.
- Conditions
- Chemotherapy-induced Neutropenia, Febrile Neutropenia, Drug-Induced, Epithelial Ovarian Cancer, Colony Stimulating Factors Adverse Reaction
- Trial name
- NCT04101760
- Testing
- Long-acting granulocyte colony stimulating factor, Short-acting granulocyte colony stimulating factor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Lei Li
Lymphoma, Non-Hodgkin, Granulocyte Colony-Stimulating Factor
Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma
This is a pharmacoeconomic research to explore the cost-effectiveness of PEG-rhG-CSF and rhG-CSF in prophylactic treatment of neutropenia in lymphoma patients. It should provide more scientific basis for clinical decision-making.
- Conditions
- Lymphoma, Non-Hodgkin, Granulocyte Colony-Stimulating Factor, Cost-Benefit Analysis
- Trial name
- NCT04083079
- Testing
- PEG-rhG-CSF, rhG-CSF
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Ruijin Hospital
Granulocyte Colony-stimulating Factor, Minimal Residual Disease
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
Granulocyte-colony stimulating factor (G-CSF) is konwn to have no significant effect on leukemia stem cells and has been widely used in the patients with agranulocytosis after chemotherapy.
- Conditions
- Granulocyte Colony-stimulating Factor, Minimal Residual Disease, Acute Myeloid Leukemia
- Trial name
- NCT03665480
- Testing
- G-SCF
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Healthy Allogeneic Donors, Granulocyte Colony-stimulating Factor (G-CSF) Mobilized
Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®
The study will determine the advantage of the Spectra Optia® IDL set compared to the standard collection set for collection of peripheral blood progenitor cells using the Spectra Optia® apheresis system.
- Trial name
- optiMaL (NCT01901458)
- Testing
- Spectra Optia® IDL-Set, Spectra Optia® Collection Set
- Where
- 2 sites in Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Myeloma, Bortezomib
Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of myeloma cells by blocking proteasome activity. Cyclophosphamide and dexamethasone may work in different ways to stop the growth of myeloma cells by stopping them from dividing or by…
- Conditions
- Myeloma, Bortezomib, Cyclophosphamide, Dexamethasone
- Trial name
- NCT02027220
- Testing
- G-CSF, Bortezomib, Cyclophosphamide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital of Soochow University